Pipeline
Robust Portfolio of New Drug Candidates

LISCure develops novel "Game Changers" aiming the first and best-in-class therapeutics.

R&D Pipeline
  • Indication
  • Product
  • Collaborators
  • Discovery
  • In-Vivo Efficacy
  • IND Enabling
  • Phase 1
  • Phase 2
  • Microbiome Therapeutics
  • LIVER DISEASES
    LIVER DISEASES
    IMMUNOLOGY
    NEUROSCIENCE
    NEUROSCIENCE
    NEUROSCIENCE
    ONCOLOGY
  • LB-P8
    LB-P8
    LB-P6
    LB-P4
    LB-PC01
    LB-PC02
    LB-P2L

    NASH & NAFLD

    Cholestatic Liver Disease

    Auto-immune Disease

    Parkinson’s Disease/Alzheimer’s Disease

    Parkinson's Disease

    Parkinson's Disease

    Solid Tumors

  • Bacteria-mediated
    Immunotherapy
  • ONCOLOGY
  • LB-P2D

    Solid Tumors (advanced cancers)

  • Bacterial EV
  • NEUROSCIENCE
  • LB-P4E
Microbiome Therapeutics
IndicationNASH&NAFLD
ProductLB-P8
Collaborators
Phase 1
IndicationCholestatic Liver Disease
ProductLB-P8
Collaborators
Phase 1
IndicationAuto-immune Disease
ProductLB-P6
Collaborators
Phase 1
IndicationParkinson & Alzheimer
ProductLB-P4
Collaborators
IND Enabling
IndicationParkinson
ProductLB-PC01
Collaborators
Discovery
IndicationParkinson
ProductLB-PC02
Collaborators
Discovery
IndicationSolid Tumors
ProductLB-P2L
Collaborators
In-Vivo Efficacy
Bacteria-mediated Immunotherapy
IndicationSolid Tumors
ProductLB-P2D
Collaborators
IND Enabling
Bacterial EV
IndicationNEUROSCIENCE
ProductLB-P4E
Collaborators
Discovery
  1. 01. Research Collaboration with Mayo Clinic (LB-P8 NASH)
  2. 02. Research Collaboration with Mayo Clinic (LB-P8 Rare Liver Diseases)
  3. 03. Research Collaboration with Celltrion (LB-PC01&PC02 Parkinson’s Disease)
  4. 04. Research Collaboration with The Scripps Research Institute (LB-P2D&P2L Immuno-Oncology)